Roche and Atavistik Bio Sign 2B Dollar Deal
Atavistik Bio partnered with Roche in a drug discovery agreement potentially worth nearly 2 billion dollars. The collaboration focuses on developing oral treatments for cardiovascular, kidney, and metabolic diseases using proprietary technology.
Xurve View
Insights:
Xurve View
ROCHE HOLDING AG-BR signed a drug-discovery partnership with Atavistik Bio worth up to $2B on Thursday afternoon. The deal focuses on developing oral treatments for cardiovascular, kidney, and metabolic diseases. The agreement spans multiple targets and includes $70M upfront alongside $1.9B in milestone payments.
